<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104580</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-20211021</org_study_id>
    <nct_id>NCT05104580</nct_id>
  </id_info>
  <brief_title>PrOgnostic Implications of PRe-stent Pullback Pressure GradIent and Post-stent Quantitative Flow Ratio in Patients UnderGoing Percutaneous Coronary INtervention</brief_title>
  <acronym>CHART-ORIGIN</acronym>
  <official_title>PrOgnostic Implications of PRe-stent Pullback Pressure GradIent and Post-stent Quantitative Flow Ratio in Patients UnderGoing Percutaneous Coronary INtervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the prognostic implication of pre-percutaneous&#xD;
      coronary intervention (PCI) focal or diffuse disease patterns combined with post-PCI&#xD;
      quantitative flow ratio (QFR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary diffuse disease associates with poor outcomes, but little is known about whether&#xD;
      this prognostic value retains after PCI, especially in those with good post-PCI physiologic&#xD;
      results.&#xD;
&#xD;
      QFR can provide the virtual pullback curve by depicting pressure at each point along the&#xD;
      interrogated vessel, which can be used to calculate the pullback pressure gradient (PPG)&#xD;
      index, this index has been shown to be able to suggest the physiological plaque distribution&#xD;
      and to discriminate focal from diffuse disease. Absolute quantification of coronary&#xD;
      diffuseness makes it possible to evaluate the prognostic value of baseline coronary&#xD;
      diffuseness before stent implantation, which is rarely investigated till now.&#xD;
&#xD;
      The CHART-ORIGIN study aims to investigate the independent and additive prognostic&#xD;
      implications of pre-PCI functional disease patterns assessed by PPG with post-PCI QFR in&#xD;
      vessels with stent implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vessel-oriented composite outcome</measure>
    <time_frame>at 2 years from index procedure</time_frame>
    <description>Vessel-oriented composite outcome (VOCO) including vessel related ischemia-driven target vessel revascularization, vessel-related myocardial infarction (MI), and cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or vessel-related MI</measure>
    <time_frame>at 2 years from index procedure</time_frame>
    <description>Cardiac death or vessel-related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel-related MI</measure>
    <time_frame>at 2 years from index procedure</time_frame>
    <description>Vessel-related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>at 2 years from index procedure</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven target vessel revascularization</measure>
    <time_frame>at 2 years from index procedure</time_frame>
    <description>Ischemia-driven target vessel revascularization</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1395</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>High pre-PCI PPG index and high post-PCI QFR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Low pre-PCI PPG index and high post-PCI QFR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Low post-PCI QFR regardless of pre-PCI PPG index</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quantitative Flow Ratio derived PPG</intervention_name>
    <description>From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:&#xD;
PPG index={MaxPPG20mm/â–³QFRvessel+(1-length with functional disease/Total vessel length) }/2.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1,395 patients with 1,685 target vessels with measurable QFR and PPG index from the&#xD;
        PANDA-III study (Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL&#xD;
        Biodegradable Polymer Sirolimus-eluting Stent in &quot;Real-World&quot; Practice) (NCT02017275).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with at least one vessel with measurable QFR&#xD;
&#xD;
          -  PPG index can be calculated from virtual QFR pullback curve;&#xD;
&#xD;
          -  The patient is willing to comply with specified follow-up evaluations;&#xD;
&#xD;
          -  Patients who agree to accept the follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Culprit vessels for ACS myocardial infarction;&#xD;
&#xD;
          -  Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure;&#xD;
&#xD;
          -  Patient has other medical illness (e.g., cancer, known malignancy, congestive heart&#xD;
             failure, organ transplant recipient or candidate) or known history of substance abuse&#xD;
             (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol,&#xD;
             confound the data interpretation or is associated with a limited life expectancy&#xD;
             (i.e., less than 1 year);&#xD;
&#xD;
          -  Patient has a known hypersensitivity or contraindication to aspirin, heparin,&#xD;
             clopidogrel/ticlopidine, stainless steel alloy, cobalt chromium, rapamycin,&#xD;
             styrene-butylenes-styrene or poly-lactic acid (PLA) polymer, and/or contrast&#xD;
             sensitivity that cannot be adequately pre-medicated;&#xD;
&#xD;
          -  Any significant medical condition which in the Investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study;&#xD;
&#xD;
          -  Currently participating in another investigational drug or device study or patient in&#xD;
             inclusion in another investigational drug or device study during follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Xu, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neng Dai, MD</last_name>
    <phone>+8613701997266</phone>
    <email>niceday1987@hotmail.com</email>
  </overall_contact>
  <reference>
    <citation>Xu B, Gao R, Yang Y, Cao X, Qin L, Li Y, Li Z, Li X, Lin H, Guo Y, Ma Y, Wang J, Nie S, Xu L, Cao E, Guan C, Stone GW; PANDA III Investigators. Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial. J Am Coll Cardiol. 2016 May 17;67(19):2249-2258. doi: 10.1016/j.jacc.2016.03.475.</citation>
    <PMID>27173037</PMID>
  </reference>
  <reference>
    <citation>Dai N, Hwang D, Lee JM, Zhang J, Jeon KH, Paeng JC, Cheon GJ, Koo BK, Ge J. Feasibility of Quantitative Flow Ratio-Derived Pullback Pressure Gradient Index and Its Impact on Diagnostic Performance. JACC Cardiovasc Interv. 2021 Feb 8;14(3):353-355. doi: 10.1016/j.jcin.2020.10.036. Erratum in: JACC Cardiovasc Interv. 2021 Sep 13;14(17):1963.</citation>
    <PMID>33541549</PMID>
  </reference>
  <reference>
    <citation>Dai N, Zhang R, Hu N, Guan C, Zou T, Qiao Z, Zhang M, Duan S, Xie L, Dou K, Zhang Y, Xu B, Ge J. Integrated coronary disease burden and patterns to discriminate vessels benefiting from percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021 Oct 15. doi: 10.1002/ccd.29983. [Epub ahead of print]</citation>
    <PMID>34652068</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

